Search results
23 wrz 2017 · We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201). Methods: We did an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany.
23 wrz 2017 · Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201).
5. Development of mRNA Vaccines for Prevention of Animal Infectious Diseases and Zoonoses. Currently, most of the mRNA vaccines were developed for protecting against zoonotic diseases such as Ebola, influenza, rabies, and Zika virus disease. Only limited mRNA vaccines have been developed in the veterinary field.
25 sie 2021 · The Moderna vaccine candidate mRNA-1273 was also highly effective, and showed 86.4% efficacy in volunteers ≥65 years old, in comparison with 95.6% efficacy in 18–65-year-old volunteers 131.
28 lip 2024 · This review summarizes recent research on the development of mRNA vaccines for rabies, with a brief review of mRNA rabies vaccine-related studies that have shown to be effective in preclinical animal models or clinical trials, and describes the current research status of mRNA rabies vaccines.
22 cze 2023 · Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. Open access 16 October 2020. A Rift Valley fever mRNA vaccine elicits...
1 gru 2023 · A messenger RNA (mRNA)-based vaccine is a rapid and versatile platform for relatively easy vaccine production on a large scale. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccine encoding a rabies virus glycoprotein (RABV-G).
